Intravesical administration of drugs has been used commonly in spinal cord injury patients to suppress detrusor hyperreflexia (eg oxybutynin, verapamil, terodiline) or, to initiate a micturition reflex (eg 15S 15-methyl prostaglandin F2 alpha, protaglandin E2); however, the response has been variable and sometimes, unpredictable. This prompted us to study the presence of nerve fibres in the vesical urothelium and submucosa in mucosal biopsies taken from the dome and trigone (obtained prior to performing a therapeutic procedure eg, vesical lithotripsy, or a diagnostic cystoscopy) in 47 consecutive, un selected paraplegic/tetraplegic patients with a neuropathic urinary bladder. Nerve fibres were demonstrated by routine immunohistochemical technique using commercially available monoclonal and polyvalent antibodies against S-lOO (DAKO A/S, Glostrup, Denmark) and Neurofilament (MILAB, Malmo, Sweden). Biopsy specimens were graded for the presence of nerve fibres on a 0 -3 scale for urothelium, and superficial/deep submucosa separately in a blind and randomised manner. Virtually no fibre presence was found in one paraplegic patient and no superficial or single fibres were noted in a tetraplegic patient. Absence of C-fibre hyperplasia (Grade 0) was found in nine cases (paraplegic: 4; tetraplegic: 5); Grade 1 hyperplasia was observed in 17 cases (paraplegic: 4; tetraplegic: 13); Grade 2 hyperplasia was seen in II cases (paraplegic: 7; tetraplegic 4); and Grade 3 hyperplasia was noticed in eight cases (paraplegic 3: tetraplegic: 5). The magnitude of C-fibre hyperplasia was not significantly different between paraplegic and tetraplegic patients (X 2 = 4.64; P = 0. 3262). The relationship, if any, between the degree of C fibre hyperplasia and duration of paralysis was studied by categorising patients as < 5 years, and > 5 years of paralysis. No evidence of single fibre or fibre bundle hyperplasia (Grade 0) was seen in five and six cases, grade 1 hyperplasia in six and II cases, grade 2 hyperplasia in two and nine cases, and grade 3 hyperplasia in three and five cases respectively in these two categories of patients. (X 2 = 1.92; P = 0.58). The possible relationship between C-fibre hyperplasia in the vesical mucosa/submucosa and (i) the vesical response to intravesical drug administration; (ii) the vesical urothelial proliferation arrest; (iii) the electrical stimulation of urinary bladder by implanted electrodes (sacral anterior root stimulator); and (iv) long-term indwelling urethral Foley catheter drainage, are discussed with illustrative case reports. In conclusion, mucosal biopsy and study of nerve fibres in urothelium and submucosa of neuropathic bladder has helped to generate hypotheses on the association between C-fibre hyperplasia and response to intravesical pharmacotherapy and the predictive value of such a study in identifying those patients who are likely to respond to intravesical pharmacotherapy.
Introduction
The management of the neuropathic bladder in spinal cord injury patients has changed from an emphasis on a surgical procedure such as transurethral resection of the bladder neck and division of the external urethral sphincter to a non-surgical method viz. intermittent catheterisation (whenever feasible) as this has been shown to achieve complete, low pressure emptying of the urinary bladder with few complications. However, intermittent catheterisation regimes often require adjunctive intravesical pharmacotherapy (i) to increase the bladder capacity in patients with a small capacity bladder so that they do not have to catheterise themselves very frequently, and (ii) to abolish detrusor hyperreflexia when present, in order to minimise urinary leakage between catheterisations. The success of intravesical pharmacotherapy depends on (1) the pharmacological properties of the drug administered; (2) penetration of the drug across the vesical mucosa and its absorption from the bladder; and (3) qualitative and quantitative presence of nerve fibres in the urothelium, submucosa, and detrusor muscle. Ishizuka et all demonstrated that intravesically instilled capsaicin (in normal, unanesthetized rats) induced reflex-mediated hyperactivity, probably via stimulation of neurokinin2 receptors. Intravesically administered capsaicin released neuropeptides from nerves in or immediately beneath the urothelium in the bladder and/or outflow region, and these peptides initiated a micturition reflex by afferent stimulation. Like CapSalClll, intravesically infused prostaglandin E2 facilitated micturition which was attenuated by selective blockade of Neurokinin! or Neurokinin2 receptors and, most effectively, by a combined blockade (Ishizuka et al)? This suggested that tachykinins, both neurokinin A (NK2 receptors) and substance P (NK! receptors), may be released from nerves and mediate part of the effects of PGE2. The location of such nerves may be in and/or immediately below the urothelium.
We observed that the vesical response to intravesi cally administered drugs in spinal cord injury patients is sometimes unpredictable and the magnitude of response varies from patient to patient. This prompted us to study the presence of nerve fibres in bladder mucosal biopsies obtained from spinal cord injury patients while they were undergoing some other diagnostic or therapeutic procedure on the urinary bladder. Although the presence of nerve fibres in the detrusor muscle of denervated bladders has been documented, to our knowledge, the extent and presence of (abnormal) nerve fibres in the vesical urothelium and in the vesical submucosa of neuro pathic bladders from mucosal biopsy specimens has not been characterised by immunohistochemical studies. We believe that such a study of the presence of nerve fibres in the urothelium and submucosa of spinal cord injury patients with a neuropathic bladder may contribute towards a better understanding of the vesical response to intravesically administered drugs in a given individual and also provide guidance towards selection of suitable patients who are likely to benefit by such a therapeutic regime. As of now, the choice of patients for intravesical administration of a drug is often on an empirical basis in that a given drug, say, oxybutynin is administered intravesically, and if the individual spinal cord lllJury patient shows a satisfactory therapeutic response, drug administration is continued; and intravesical pharmacotherapy is discontinued if the patient fails to show an optimal response. Quantitative and qualitative study of nerve fibres and receptors in the urothelium and vesical submucosa in spinal cord injury patients may help towards selection of cases who may have higher probability of responding to a given drug regime.
Neural input has a significant role in regulating the growth of the bladder and innervation influences tissue levels of nerve growth factor in the urinary bladder.
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The presence of nerve fibres in the urothelium and submucosa may provide trophic factors for vesical urothelial proliferation. Vesical urothelial proliferation arrest has been demonstrated in spinal cord injury patients by immunohistochemical study with prolifer ating cell nuclear antigen (PCNA) and Ki 67 antigen (using the monoclonal antibodies suitable for detection of the recombinant DNA based MIB-I fragment of the Ki 67 antigen). 4 The observed urothelial prolifera tion arrest in the spinal cord injury patients may be a contributory factor for their becoming prone to the development of cystitis. Thus the presence of adequate number of normally (physiologically) functioning nerve fibres or conversely, paucity of nerve fibres or presence of abnormal nerve fibres in the vesical urothelium and submucosa may have a bearing on the proliferation status of vesical urothelium in spinal cord injury patients and, in turn, to their propensity for development of recurrent cystitis. Further, in cystitis, there may be an exaggerated prostanoid production leading to intense activation of sensory nerves, increasing the afferent input from the bladder mucosa. s This may possibly explain why some spinal cord injury patients develop a severe degree of autonomic dysreflexia during an episode of acute cystitis whereas many other tetraplegic and paraplegic patients with a lesion above T-6 level do not exhibit features of autonomic dysreflexia during an episode of acute urinary tract infection and cystitis. Continuous irritation of the bladder mucosa, for example by an indwelling catheter, over a period of time (many months to years as we have seen female patients with a neuropathic bladder who have been on indwelling urethral catheter regime for over three decades), may result in neural stimulation with secondary changes in the bladder mucosa. It is thus possible that squamous metaplasia observed in those spinal cord injured patients on long-term indwelling urethral catheter drainage may indeed by a nerve mediated phenomenon. In order to understand these complex issues on altered anatomy and physiology of the neuropathic bladder, we carried out a preliminary investigation by studying prospectively the pattern of C-fibres in the vesical urothelium and vesical submucosa in bladder mucosal biopsy specimens of spinal cord injury patients by immunohistochemical studies.
Patients and methods

Study population
Forty-seven consecutive adult spinal cord injury patients who were otherwise scheduled for a cysto scopy prior to treatment of bladder stone(s) (n = 22), urethral diverticulum (n = 2), urethral calculus (n = 1), urethral stricture (n = 1), and prostatic urethral calculus (n = 1), division of external urethral sphincter and transurethral resection of bladder neck (n = 6), inser tion of 11 ureteral stent (as the initial step before shock wave lithotripsy of renal calculus) (n = 3); removal of 11 stent (n = 2), for evaluation of haematuria (n = 8), or prior to performing ascending ureteropyelography in a case of pelviureteric junction obstruction were the subjects of this study. The nature of the investigation was explained to the patient and to his/her carer(s) and written informed consent was obtained. Cystoscopy was performed with a Storz 22 Fr. rigid cystoscope in the lithotomy position. Cold-cup biopsy was taken randomly under vision from the dome and from the trigone of the urinary bladder. Any bleeding point was then fulgurated with diathermy electrode. All partici pants underwent the procedure without any intra operative or post-operative complication. Performance of bladder biopsy did not result in any additional morbidity to any of the patients and did not increase the duration of hospitalisation; the cervical spinal cord injury patient with C-5 tetraplegia who underwent 11 stenting of the ureter (as the initial procedure prior to shock wave lithotripsy of renal calculus), and bladder biopsy was discharged home the same evening after the procedures were carried out uneventfully.
Tissue processing, histology Bladder biopsies were fixed by immediate immersion in 0.1 M, phosphate buffered, 4% formaldehyde, pH 7.4 for a minimum of 6 and a maximum of 12 h. After dehydration, specimens were routinely processed to paraplast using vacuum processing and a maximum temperature of 53°C. Five micron sections were cut and mounted routinely for Haematoxylin and Eosin staining. All the biopsy specimens were evaluated together by a Pathologist who was unaware of the site of biopsy and of relevant clinical details.
Immunohistochemistry
Nerve tissue of sympathetic/parasympathetic and sensory type was identified using a combination of two antibodies. A polyvalent antibody against S-100 (neural crest antigen found in high density on all neural crest derived tissue, ie on both axons and Schwann cells) was chosen as the screening antibody in view of the high contrast provided in routine immunohistochemistry. The disadvantage of using this antibody is that the circulating macrophages are also stained positive (being similarly neural crest tissue derived). But this was overcome by additionally staining for Neurofilament, a well defined antigen epitope found on the 200 kD neurofilament protein specifically found in the axons of peripheral nerve tissue as part of the axon located neurofilaments. With lower antigenic density, this antibody is less suitable for screening purposes.
Five micron sections were routinely stained for Neurofilament and S-100 using commercially available (Figure 3 ). In case no C-fibre was (virtually) present, this observation was recorded separately.
Results
The clinical details and results of immunohistochemical studies with S-100 and neurofilament on bladder biopsies are given in Table 1 . Virtually no fibre presence was found in one paraplegic patient and no superficial or single fibres were noted in a tetraplegic patient. Absence of C-fibre hyperplasia (Grade 0) was found in nine cases (paraplegic: 4; tetraplegic: 5); Grade 1 hyperplasia was observed in 17 cases (paraplegic: 4; tetraplegic: 13); Grade 2 hyperplasia was seen in II cases (paraplegic: 7; tetraplegic: 4); and Grade 3 hyperplasia was noticed in eight cases (paraplegic: 3; tetraplegic: 5). The magnitude of C fibre hyperplasia did not vary significantly between paraplegic and tetraplegic patients (X 2 = 4.64; p= 0. 3262). The magnitude of C-fibre hyperplasia in patients with bladder stone(s) (n = 22) did not differ significantIt' from those with other clinical conditions (n = 25) (X = 0.603; P = 0.9626). Intra-urothelial presence of nerve fibres was detected in a patient with evident squamous metapla sia ( Figure 4 ). The development of thick calibre, peripheral nerve like fibre bundles was limited to cases with Grade 3 hyperplasia, but in such cases very thick bundles could be found in an abnormal, very superficial location ( Figure 5 ). Granulation tissue development, such as in the presence of calculus was generally associated with the emergence of large amounts of small and intermediate calibre axon bundles, closely associated with the proliferating Figure 1 Microphotograph of trigone urinary bladder biopsy featuring Grade I degree of nerve fibre increase. Note the relative absence of stained axons in the very superficial mucosa and the relatively small calibre of the stained axon bundles in deeper parts of the mucosa. Five micron paraffin section, stained with monoclonal antibody against Neurofilament, Haematoxylin counterstain. Micro scopical magnification lOa x blood vessels ( Figure 6 ) and could easily be differentiated from the pattern of fibre hyperplasia under study.
Four patients underwent bladder biopsies twice (lP; BC; 11; PF); the time interval between the two biopsies was 4, 11, 21, and 8 months respectively; the indications for cystoscopy were insertion/removal of 11 stent in IP; electro hydraulic lithotripsy of bladder calculus in PF and BC; and removal of prostatic urethral calculi/transurethral resection of prostate in 11. Overall grading of C-fibre hyperplasia was 0 and 3 in IP; 1 and 3 in BC; 1 and 1 in 11 and 3 and I in PF in the two sets of biopsies taken at different time points. This interesting observation suggests possible temporal variation in the magnitude of bladder mucosal and submucosal C-fibre hyperplasia in a given spinal cord injury patient. Thus the degree of C-fibre hyperplasia may vary in the same patient over 
Discussion
MUltiple factors may contribute to the development of C-fibre hyperplasia in the vesical mucosa/submucosa and these include (i) denervation/decentralization of The relationship between the degree of C fibre hyperplasia and duration of paralysis was studied by categorising patients into (i) < 5 years, and (iii) > 5 years after developing neuropathic bladder. No evidence of single ·fibre or fibre bundle hyperplasia (Grade 0) was seen in five and six cases; grade I hyperplasia in six and 11 cases; grade 2 in two and nine cases; and grade 3 in three and five cases respectively in these two categories of patients. (X 2 = 1.92; P = 0.58). Presence of an indwelling urethral Foley catheter, by constant mechanical irritation, may induce C-fibre hyperplasia. Of the eight patients with grade 3 C fibre hyperplasia, four were on long-term indwelling urethral Foley catheter drainage. Possible contributory factors to the development of grade 3 hyperplasia in the other four cases with grade 3 C-fibre hyperplasia are: electrical stimulation of the bladder in one (PR); presence of JJ ureteral stent in another (IP), this tetraplegic patient had grade 0 hyperplasia before insertion of JJ stent and 4 months later was found to have developed grade 3 hyperplasia; long-term indwel ling catheter drainage in PR although at present she is practising intermittent catheterisation with adjunctive pharmacotherapy; repeated electro-ejaculation in MS.
Ishizuka et aP demonstrated that prostaglandin E2 when gIven intravesically, may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium. These tachyki nins, in turn, initiate a micturition reflex by stimulating neurokinin] and neurokinin2 receptors. This illustrates the important role played by nerve fibres in the vesical urothelium and submucosa in the context of intravesical drug administration, a ther apeutic modality which is becoming increasingly popular for the management of the neuropathic bladder in spinal cord injury patients. The drugs which are being administered intravesically in spinal cord injury patients include oxybutynin, prostaglandin E2, 15(S) 15-methyl prostaglandin F2 alpha, verapamil, atropine, phentolamine, terodiline, bupivacaine, and capsaicin.
The following three case reports illustrate the possible relevance of C fibre hyperplasia in vesical mucosa and submucosa to clinical pharmacotherapy of intravesical drug administration in spinal cord injury patients with a neuropathic bladder.
Case 1 AR, a 50 year old male with T -7 paraplegia due to transverse myelitis and detrusor hyperreflexia was advised to have intermittent catheterisation and adjunctive pharmacotherapy with oxybutynin Trigone biopsy showed patchy increase of axonal fibres mainly associated with proliferating blood vessels. Dome biopsy showed some increase of thick bundles in deeper layers of mucosa Trigone biopsy revealed no proliferation of single fibre axons or fibre bundles in the superficial or deep mucosa and submucosa or in the muscle tissue. Dome biopsy showed virtually no fibre presence with S-100 and neurofilament stain which is confirmed by the absence of single axons administered intravesically three times a day in the form of a commercially available solution containing 5 mg of oxybutynin in 30 m!. He diligently carried out this regime, but there was no clinical response to intravesical oxybutynin therapy; he continued to leak urine between catheterisations even though he was performing intermittent catheterisation six times a day. He ultimately preferred to have an indwelling urethral catheter drainage despite its potential disadvantages. Immunohistochemical study of bladder mucosal biopsy with S-lOO and neurofilament showed no evidence of (grade 0) nerve hypertrophy.
Case 2 MC, a 36 year male with spinal cord injury at L-l level did not demonstrate a satisfactory clinical response to intravesical oxybutynin therapy (5 mg of oxybutynin in 30 ml administered intravesically three times a day), and he discontinued its use. Immunohistochemical study of bladder mucosal biopsy in this paraplegic also showed absence of (grade 0) nerve hypertrophy.
Case 3
In contrast to the above two cases, PR, a 48 year old female with paraplegia due to tuberculous meningitis, showed a satisfying clinical response to intravesical oxybutynin therapy (5 mg of oxybutynin in 30 ml, administered intravesically three times a day) which was prescribed as an adjunctive measure to intermittent catheterisation to prevent urine leaks between cathe terisation. Bladder mucosal biopsy showed extensive hypertrophy of thin naked axons in superficial submucosa seen both in S-lOO and neurofilament immunohistochemical studies. Although the above three patients represent only anecdotal case reports, these observations suggest a possible functional relationship between the presence/ virtual absence of, and hypertrophy of nerve fibres in mucosa and vesical submucosa in spinal cord injury patients and the response to intravesical drug (eg oxybutynin) therapy justifying further clinical research aimed at recognising the patient who may have a lower probability of responding to a given drug regime and in whom this treatment modality may not be effective.
Paucity of, or virtual absence of C-fibres, a source of trophic factors such as VIP, in the vesical mucosa and submucosa may be considered a possible cause of urothelial proliferation defect or arrest. Immuno pathological analysis of the bladder trigone biopsy of AN (H95/1576), (a 61 year old male traumatic paraplegic with T -10 level since 30-08-76), using monoclonal antibodies against neurofilament and S-100 showed no proliferation of single fibre axons or fibre bundles in the superficial, or deep mucosa, submucosa, and muscle tissue. With antibodies to proliferating cell nuclear antigen, approximately 20% -30% labelling was found in areas linked by urothelium; with antibodies to MIB-l, in the urothelial layers, only \ % of the nuclei stained positive indicating complete PCNA, MIB-I dissocia tion and proliferation arrest. Similarly, immunopatho logical analysis of the bladder dome biopsy of BL (H95/1273, a 60 year old male traumatic tetraplegic patient), using monoclonal antibodies against S-\OO and neurofilament showed no evidence of single fibres or fibre bundle hyperplasia in the mucosa. Mono clonal antibodies against proliferating cell nuclear antigen showed approximately 30 -40% positive labelling over two-thirds of the height of the mucosa. With antibodies to MIB-\, virtually no effective labelling was seen. Thus in this patient with no evidence of single fibre or fibre bundle hyperplasia, complete PCNA, MIB-\ dissociation with prolifera tion arrest was observed. Although at present insight into the cause/effect nature of this association does not allow for conclusive interpretation, the relationship between fibre hyperplasia and proliferation dependent cell surface changes facilitating bacterial colonisation require further exploration.
Electrical stimulation of urinary bladder by implanted electrodes (sacral anterior root stimulator) has been shown to decrease the frequency of urinary tract infection. The reduction in the episodes of cystitis in these spinal cord Injury patients following implantation of sacral anterior root stimulator was, so far, believed to be due to more efficient emptying of the urinary bladder and consequent decrease in residual urine. It is also possible that electrical stimulation of urinary bladder leads to release of trophic factors from the vesical mucosal and sub mucosal nerves and improved proliferation status of vesical urothelium. Two patients in this study had undergone implantation of an anterior sacral root stimulator. PR, a 33 year old traumatic paraplegic patient since 05-02-\982, had had an anterior sacral root stimulator with extradural placement of electro des inserted on 29-05-\992. The bladder biopsy taken on 22-05-\995 (H95/1407-08) showed grade 3, C-fibre hyperplasia. Trigone biopsy revealed there was extensive increase of single axons in the superficial submucosa. Slightly deeper but still superficially, there was an increase of bundles of axons of intermediate calibre. Even deeper in the wall, associated with smooth muscle, were thick nerve bundles of periph eral nerve morphology. Dome biopsy, featuring almost identical changes, showed extensive increase in the superficial submucosa of single thin axons. The bladder biopsy of the other patient 11, a 37 year old male who sustained traumatic tetraplegia at C-5 level on 29-11-1980, had undergone sacral anterior root stimulator implantation in March 1982 and bilateral posterior rhizotomy S2 to Ss on 15-09-1987 showed well-defined thick nerve bundles in deeper layers as well as relatively close to vesical mucosa both with neurofilament and S-100 staining (H93/3250/2). At present, it is not known what role electrical stimula tion of anterior sacral roots S2,S3, and S4 may have on the development of such C-fibre hyperplasia in the vesical mucosa and submucosa. In contrast however, the availability of such a stimulus dispersing fibre system as in the above patients with C-fibre hyperplasia, will modulate the effect of sacral anterior root stimulation at the pre-ganglionic level. Subse quent changes in the kinetics of epithelial turnover may well be explained either by the changes in bladder function or through alterations in the release of trophic factors. This opportunity for further elucidat ing the beneficial effects of neural stimulation warrants further research in experimental models. If alterations of cell proliferation occur in the absence of, or preceding, fibre hyperplasia, a direct effect of (neuro mechanical) stimulation may be assumed. If however, such changes are observed only after, and only in cases where nerve fibre hypertrophy has occurred, a direct relationship through the release of trophic factors may be assumed.
Thus in summary, although clarifications on cause and affect relationship of C-fibre hyperplasia in vesical mucosa/submucosa observed in patients with a neuropathic bladder requires further study, a pre viously unappreciated fact remains that a significant proportion of spinal cord injury patients with a neuropathic bladder exhibit this phenomenon of C fibre hyperplasia whereas some paraplegic and tetraplegic patients do not exhibit it for reasons presently not well understood. Due to the limited number of cases available for assessment, it was not possible to draw any firm conclusion on the possible clinical relationship between C-fibre hyperplasia and response to intravesical pharmacotherapy. However, this concept, if proved correct, may open new avenues for future investigations in terms of qualitative and quantitative assessment of nerve fibres and receptors in vesical mucosa/submucosa to predict those patients who may have low probability for exhibiting a therapeutic response to intravesical pharmacotherapy with a particular drug so that alternative strategies may then be considered earlier to the benefit of the patient. The possibility that sacral nerve stimulation has a trophic effect on urothelium, even if this requires mediation through (not always achieved/found) nerve fibre hyperplasia may further add to justifications of the bladder biopsy (in itself an invasive test, although with the advent of flexible cystoscopy, the morbidity of bladder biopsy may be less) for study of nerve fibres hyperplasia, cholinergic, adrenergic, peptidergic, and growth factor receptors and urothelial proliferation status. Why some spinal cord injury patients develop C-fibre hyperplasia relatively early and why some do not exhibit this at all, requires further study, especially as the overall effect associated with this change is perhaps, positive as a whole and not detrimental to the bladder function. The possible confounding role of the chronic mechanical stimulation of urothelium by indwelling catheters (at least at some time in the past for many patients) and functional relationship between C-fibre hyperplasia and squamous metaplasia (three of the eight patients with grade 3 C-fibre hyperplasia (trigone biopsy of BC who. has been on indwelling catheter drainage, dome and trigone biopsy of PR who was on indwelling catheter drainage, and dome biopsy of IP who had 11 stent of left ureter) showed features of squamous metaplasia) requires further assessment. It should be emphasised that unlike a laboratory model, in a clinical study on spinal cord injury patients, many variables are inherently present viz. duration of paralysis, level of paralysis, whether the lesion is complete or incomplete, presence of a syrinx, number of episodes of acute urinary tract infection, therapeutic interventions such as type and duration of a particular form of bladder drainage, presence of bladder stone(s) and if so, the duration of its presence in the bladder before it was removed, whether a sacral anterior root stimulator was implanted and if so, how long after the spinal cord injury was it implanted, the duration of its use, whether a baclofen pump for intrathecal delivery of baclofen was implanted and if so, how long after the injury it was implanted and how long has it been in use, etc. All these variables may affect bladder physiology and functional anatomy and what we observe at a particular time point in a given spinal cord injury patient is only a cross-sectional view and indeed, no two spinal cord injury patients are identical. It is important that we keep this issue of diversity in mind while drawing any inferences on pathophysiology of neuropathic bladder in patients with spinal cord injury.
In conclusion, mucosal biopsy and study of nerve fibres in the urothelium and submucosa of the neuropathic bladder has helped to generate hypoth eses on the association between C-fibre hyperplasia and response to intravesical pharmacotherapy and predictive value of such a study in identifying those patients who are likely to respond to intravesical pharmacotherapy.
